Sterile vs Nonsterile Compounding (USP 795, 797, 800)
Educational only, not medical advice. This guide explains general US pharmacy-technician topics. Follow your training, your pharmacist, your state board and the official references for real patients.
Compounding is preparing a medication to fit a patient's needs when a commercial product will not do: a liquid for a patient who cannot swallow tablets, a dye-free version, or an IV bag mixed for one patient. Three USP general chapters set the quality standards most state boards of pharmacy enforce, and individual states may adopt them differently or add stricter rules. This guide covers what a technician needs to know about each one, including the revised chapters that became official in 2023.
What compounding is, and the three USP chapters
Compounding means combining, mixing or altering ingredients to create a preparation tailored to a patient. Federal law describes two routes:
- Section 503A (pharmacies): compounding by a licensed pharmacist or physician, generally based on a prescription for an identified patient. These preparations are exempt from federal current good manufacturing practice (CGMP) rules, so USP standards and state boards do most of the oversight.
- Section 503B (outsourcing facilities): facilities that compound sterile drugs, register with FDA and must follow CGMP.
Compounded preparations are not FDA-approved, which is one reason quality standards matter so much.
Three chapters at a glance
| Chapter | Covers | Status |
|---|---|---|
| USP <795> | Nonsterile preparations (oral liquids, creams, capsules) | Revision official November 1, 2023 |
| USP <797> | Sterile preparations (injections, IV bags, eye drops) | Revision official November 1, 2023 |
| USP <800> | Handling hazardous drugs in any health care setting | Official since December 1, 2019; compendially applicable November 1, 2023 |
USP <800> works alongside the other two: a hazardous drug compounded as a sterile preparation must meet both <797> and <800>.
Nonsterile compounding under <795>
A key topic in <795> is the default beyond-use date (BUD), used when there is no USP compounded preparation monograph or preparation-specific stability data. BUDs depend on water activity (aw): a preparation with aw of 0.6 or higher is aqueous; below 0.6 is nonaqueous.
- Aqueous, not preserved: 14 days, refrigerated
- Aqueous, preserved: 35 days
- Nonaqueous oral liquids: 90 days
- Other nonaqueous dosage forms (such as capsules or anhydrous ointments): 180 days
A BUD can be shorter if an ingredient expires sooner.
Worked example. A preserved aqueous oral suspension is compounded on March 3. March has 31 days, so March 3 + 28 days = March 31, and 7 more days reach April 7. The BUD is April 7 (28 + 7 = 35 days).
Sterile compounding under <797>: the categories
The 2023 revision replaced the old low-, medium- and high-risk levels with categories based mainly on where a compounded sterile preparation (CSP) is made and how long it may be kept.
- Immediate-use CSPs: for urgent situations under strict conditions (for example, no more than 3 different sterile products). Administration must begin within 4 hours of the start of preparation.
- Category 1: may be made in a primary engineering control inside an unclassified segregated compounding area (SCA) or a cleanroom suite. BUD: 12 hours or less at controlled room temperature, or 24 hours or less refrigerated.
- Category 2: must be made in a cleanroom suite. BUDs are longer and come from a table that depends on how the CSP was made and stored. For example, a CSP made aseptically from only sterile ingredients, without sterility testing, gets 4 days at room temperature, 10 days refrigerated or 45 days frozen.
- Category 3: CSPs that undergo sterility testing (plus endotoxin testing when applicable) and meet additional requirements. They may be given longer BUDs than Category 2, but never beyond the chapter's maximum limits.
Worked example. A technician starts compounding a Category 1 CSP at 9:00 AM.
- Stored at room temperature: 9:00 AM + 12 hours = 9:00 PM the same day.
- Stored in the refrigerator: 9:00 AM + 24 hours = 9:00 AM the next day.
If it were an immediate-use CSP started at 10:15 AM, administration would have to begin by 10:15 + 4 hours = 2:15 PM.
BUDs are not cumulative: moving a CSP from room temperature to the refrigerator or freezer does not extend its original BUD, and administration must begin before the BUD passes.
The cleanroom suite: ISO classes, PECs and C-SECs
Air cleanliness is graded by ISO class: the lower the number, the fewer airborne particles. FDA's aseptic processing guidance gives these limits for particles 0.5 µm and larger per cubic meter:
- ISO 5: 3,520 (the critical work zone)
- ISO 7: 352,000
- ISO 8: 3,520,000
A cleanroom suite for Category 2 work has three layers:
- Primary engineering control (PEC): the ISO 5 device where sterile work happens, such as a laminar airflow workbench, biological safety cabinet, compounding aseptic isolator (CAI) or compounding aseptic containment isolator (CACI).
- Buffer room: ISO 7 or better, holding the PEC.
- Ante-room: ISO 8 or better, where hand hygiene and garbing take place (ISO 7 or better if it opens into a negative-pressure buffer room, as for hazardous drugs).
Hazardous drugs under <800> add containment:
- A C-PEC (containment PEC) protects the worker as well as the product.
- The C-SEC (containment secondary engineering control) is the room holding the C-PEC. It is externally vented and kept at negative pressure, 0.01 to 0.03 inches of water column relative to adjacent areas.
- Sterile hazardous compounding uses either an ISO 7 negative-pressure buffer room or a containment segregated compounding area (C-SCA): an unclassified, externally vented, negative-pressure room with at least 12 air changes per hour. Only Category 1 hazardous CSPs may be made in a C-SCA.
Hand hygiene and garbing
The revised <797> lets each facility set the exact order in its written procedures, often based on where the sink is. The guiding principle is to don the dirtiest items first and finish with sterile gloves. A typical sequence:
- Shoe covers or dedicated shoes
- Head and facial hair covers
- Face mask (eye protection when required)
- Hand hygiene: wash hands and forearms to the elbows with soap and water, then dry
- Gown
- Alcohol-based hand rub, allowed to dry
- Sterile gloves, put on in the classified area or SCA
Staff are checked with gloved fingertip and thumb sampling as part of garbing competency.
Beyond-use date vs expiration date
- An expiration date is set by the manufacturer for a commercial product, based on stability studies of that product in its original packaging.
- A beyond-use date is assigned by the compounder to a compounded preparation. It is the date, or date and time, after which the preparation must not be used, counted from the date and time compounding began.
A vial's expiration date tells you whether the ingredient is still good; the BUD tells you how long the finished preparation is good.
Key takeaways
- <795> covers nonsterile, <797> sterile, and <800> hazardous drug handling.
- Revised <795> and <797> became official November 1, 2023, with CSP Categories 1, 2 and 3.
- Category 1 CSPs: 12 hours or less at room temperature, 24 hours or less refrigerated.
- PEC is ISO 5, buffer room ISO 7 or better, ante-room ISO 8 or better (ISO 7 when it opens into a negative-pressure hazardous-drug room).
- Garb dirtiest to cleanest; sterile gloves go on last.
- Expiration dates come from manufacturers; BUDs come from the compounder.
Quick check
Q1. A Category 1 CSP was compounded at 2:00 PM and is refrigerated. What is the latest BUD?
Answer: 2:00 PM the next day. Category 1 allows 24 hours or less when refrigerated.
Q2. What is the default BUD for a non-preserved aqueous nonsterile preparation?
Answer: 14 days, refrigerated. Aqueous (aw of 0.6 or more) preparations without a preservative support microbial growth.
Q3. What ISO class must the ante-room for Category 2 compounding meet?
Answer: ISO 8 or better. It is the transition space between unclassified areas and the ISO 7 buffer room.
Practice these in Pillworks Idle.
Sources
- USP — General Chapter <797> Pharmaceutical Compounding—Sterile Preparations
- USP — General Chapter <795> Pharmaceutical Compounding—Nonsterile Preparations
- USP — <797> FAQs (updated December 11, 2023)
- USP — <800> FAQs (updated January 21, 2026)
- USP-NF — Commentary on the revision of General Chapter <795> (November 2022)
- USP-NF — Commentary on the revision of General Chapter <797> (November 2022)
- FDA — FD&C Act Provisions that Apply to Human Drug Compounding
- FDA — Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing